Table 2 Frequencies of specific clinical and pathologic features in colorectal cancer according to WRN methylation and CIMP status
Clinical and pathologic features | Total N | All cases WRN methylation | P-value | CIMP-high WRN methylation | P-value | CIMP-low/0 WRN methylation | P-value | |||
|---|---|---|---|---|---|---|---|---|---|---|
(+) | (−) | (+) | (−) | (+) | (−) | |||||
All cases | 903 | 266 | 637 | 119 | 14 | 128 | 615 | |||
Men | 405 | 107 | 298 | 41 | 2 | 56 | 293 | |||
Women | 498 | 159 | 339 | 78 | 12 | 72 | 322 | |||
Age | ||||||||||
Total examined | 866 | 258 | 608 | 116 | 14 | 123 | 586 | |||
<60 | 196 | 43 (17%) | 153 (25%) | 9 (7.8%) | 1 (7.1%) | 28 (23%) | 151 (26%) | |||
60–69 | 370 | 120 (47%) | 250 (41%) | 57 (49%) | 6 (43%) | 57 (46%) | 239 (41%) | |||
≥70 | 300 | 95 (37%) | 205 (34%) | 50 (43%) | 7 (50%) | 38 (31%) | 196 (33%) | |||
Tumor location | ||||||||||
Total examined | 522 | 167 | 355 | 71 | 10 | 82 | 339 | |||
Proximal | 248 | 125 (75%) | 123 (35%) | <0.0001 | 65 (92%) | 10 (100%) | 48 (59%) | 111 (33%) | <0.0001 | |
Distal | 274 | 42 (25%) | 232 (65%) | 6 (8.5%) | 0 | 34 (41%) | 228 (67%) | |||
Tumor differentiation | ||||||||||
Total examined | 885 | 264 | 621 | 119 | 14 | 126 | 600 | |||
Well/moderate | 802 | 221 (84%) | 581 (94%) | <0.0001 | 83 (70%) | 10 (71%) | 120 (95%) | 566 (94%) | ||
Poor | 83 | 43 (16%) | 40 (6.4%) | 36 (30%) | 4 (29%) | 6 (4.8%) | 34 (5.7%) | |||
Mucinous/signet ring cell features | ||||||||||
Total examined | 782 | 247 | 535 | 111 | 14 | 118 | 515 | |||
Non-mucinous carcinoma | 471 | 98 (40%) | 373 (70%) | <0.0001 | 37 (33%) | 9 (64%) | 0.04 | 54 (46%) | 361 (70%) | <0.0001 |
Mucinous 1–100% | 311 | 149 (60%) | 162 (30%) | 74 (67%) | 5 (36%) | 64 (54%) | 154 (30%) | |||
1–49% | 191 | 81 (33%) | 110 (21%) | 34 (31%) | 2 (14%) | 39 (33%) | 106 (21%) | |||
≥50% | 120 | 68 (28%) | 52 (9.7%) | 40 (36%) | 3 (21%) | 25 (21%) | 48 (9.3%) | |||
Non-signet ring call carcinoma | 721 | 214 (87%) | 507 (95%) | <0.0001 | 90 (81%) | 11 (79%) | 108 (92%) | 490 (95%) | ||
Signet ring cells 1–100% | 61 | 33 (13%) | 28 (5.2%) | 21 (19%) | 3 (21%) | 10 (8.5%) | 25 (4.9%) | |||
1–49% | 46 | 29 (12%) | 17 (3.2%) | 18 (16%) | 3 (21%) | 9 (7.6%) | 14 (2.7%) | |||
≥50% | 15 | 4 (1.6%) | 11 (2.1%) | 3 (2.7%) | 0 | 1 (0.8%) | 11 (2.1%) | |||
Tumor infiltrating lymphocytes | ||||||||||
Total examined | 877 | 258 | 619 | 116 | 14 | 124 | 597 | |||
Absent/mild | 778 | 195 (76%) | 583 (94%) | <0.0001 | 69 (59%) | 10 (71%) | 111 (90%) | 567 (95%) | 0.02 | |
Moderate/severe | 99 | 63 (24%) | 36 (5.8%) | 47 (41%) | 4 (29%) | 13 (10%) | 30 (5.0%) | |||
Crohn's-like reaction | ||||||||||
Total examined | 674 | 197 | 477 | 87 | 12 | 94 | 458 | |||
Absent/mild | 611 | 158 (80%) | 453 (95%) | <0.0001 | 56 (64%) | 10 (83%) | 88 (94%) | 436 (95%) | ||
Moderate/severe | 63 | 39 (20%) | 24 (5.0%) | 31 (36%) | 2 (17%) | 6 (6.4%) | 22 (4.8%) | |||
Peritumoral lymphocytic reaction | ||||||||||
Total examined | 879 | 259 | 620 | 116 | 14 | 125 | 598 | |||
Absent/mild | 782 | 211 (81%) | 571 (92%) | <0.0001 | 83 (72%) | 11 (79%) | 112 (90%) | 553 (92%) | ||
Moderate/severe | 97 | 48 (19%) | 49 (7.9%) | 33 (28%) | 3 (21%) | 13 (10%) | 45 (7.5%) | |||
